BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Company News  |  Other News

Inception 4 Inc., Inception Sciences, Bayer ophthalmic news

Bayer's Bayer HealthCare AG unit, Versant Ventures and drug discovery company Inception Sciences launched Inception 4 to conduct early research to develop treatments for ophthalmic disorders. Versant will provide equity financing, and Bayer will provide undisclosed milestone-based funding.

Bayer will have an exclusive option to acquire Inception 4 under certain undisclosed conditions. Financial...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >